(R)-4-((3R,5S 7R,8R,9S,10S,13R,14S,17R)-3-hydroxy-7-methoxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-1-(pyrrolidin-1-yl)pentan-1-one

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: (R)-4-((3R,5S 7R,8R,9S,10S,13R,14S,17R)-3-hydroxy-7-methoxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-1-(pyrrolidin-1-yl)pentan-1-one
• 英文别名: (4R)-4-[(3R,5S,7R,8R,9S,10S,13R,14S,17R)-3-hydroxy-7-methoxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]-1-pyrrolidin-1-ylpentan-1-one
• 化学式: C₂₉H₄₉NO₃
• 分子量: 459.713
• InChiKey: CBUNDPPKHQGBSY-NKRMQULXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.9
• 重原子数：
  33
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.97
• 拓扑面积：
  49.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  鹅去氧胆酸 在 咪唑 、 2,6-二叔丁基吡啶 、 四丁基氟化铵 、 三乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 四氢呋喃 、 吡啶 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 48.0h， 生成 (R)-4-((3R,5S 7R,8R,9S,10S,13R,14S,17R)-3-hydroxy-7-methoxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-1-(pyrrolidin-1-yl)pentan-1-one
  参考文献：
  名称：

  7-Methylation of Chenodeoxycholic Acid Derivatives Yields a Substantial Increase in TGR5 Receptor Potency

  摘要：

  TGR5 agonists are potential therapeutics for a variety of conditions including type 2 diabetes, obesity, and inflammatory bowel disease. After screening a library of chenodeoxycholic acid (CDCA) derivatives, it was determined that a range of modifications could be made to the acid moiety of CDCA which significantly increased TGR5 agonist potency. Surprisingly, methylation of the 7-hydroxyl of CDCA led to a further dramatic increase in potency, allowing the identification of 5.6 nM TGR5 agonist 17.

  DOI：

  10.1021/acs.jmedchem.9b00770

文献信息

• THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF
  申请人：REGENTS OF THE UNIVERSITY OF MINNESOTA

  公开号：US20200376007A1

  公开（公告）日：2020-12-03

  The invention provides a compound of formula (I): or a salt thereof, wherein R 1 , R 2 , R 3 , R 4 and R 6 have any of the values described in the specification, as well as compositions comprising a compound of formula (I). The compounds are agonists of the TGR5 receptor.

  该发明提供了一个化合物的结构式(I)：或其盐，其中R1、R2、R3、R4和R6可以取得规范中描述的任何值，以及包含结构式(I)化合物的组合物。这些化合物是TGR5受体的激动剂。
• 7-Methylation of Chenodeoxycholic Acid Derivatives Yields a Substantial Increase in TGR5 Receptor Potency
  作者：Ali Nakhi、Connor M. McDermott、Kristen L. Stoltz、Kristen John、Jon E. Hawkinson、Elizabeth A. Ambrose、Alexander Khoruts、Michael J. Sadowsky、Peter I. Dosa

  DOI：10.1021/acs.jmedchem.9b00770

  日期：2019.7.25

  TGR5 agonists are potential therapeutics for a variety of conditions including type 2 diabetes, obesity, and inflammatory bowel disease. After screening a library of chenodeoxycholic acid (CDCA) derivatives, it was determined that a range of modifications could be made to the acid moiety of CDCA which significantly increased TGR5 agonist potency. Surprisingly, methylation of the 7-hydroxyl of CDCA led to a further dramatic increase in potency, allowing the identification of 5.6 nM TGR5 agonist 17.